# US 2003/0223989 A1 · CD137 agonists to treat patients with IgE-mediated conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0223989 A1
- Document ID: US20030223989A1
- Status: Published application
- Kind: A1
- Application number: 10/420,050
- Filed: 2003-04-18
- Published: 2003-12-04
- Earliest claimed: 2002-04-18
- Inventors: John D. Pluenneke
- Web page: https://patentgrep.com/patent/US20030223989A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

There are disclosed methods for treating conditions mediated by IgE, comprising administering a CD137 agonist to a mammal afflicted with such a condition. CD137 agonists include CD137 ligand (CD137L) and agonistic antibodies to CD137; mammals to be treated include humans. Conditions mediated by IgE include asthma, atopic dermatitis, and allergy. CD137 agonists are also useful for treating conditions characterized by delayed eosinophil apoptosis, including nasal polyps and hypereosinophilic syndrome. Patients to be treated may be afflicted with, or at risk for, one or more of these conditions.

## Claims

### Claim 1

A method for treating a condition mediated by IgE, comprising administering a CD137 agonist to a mammal afflicted with such a condition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CD137 agonist is selected from the group consisting of CD137 ligand (CD137L) and agonistic antibodies to CD137.

### Claim 3 (depends on 2)

The method of claim 2, wherein the CD137 agonist is a CD137L polypeptide selected from the group consisting of:
(a) a polypeptide comprising amino acids x through y of SEQ ID NO:2, wherein x is selected from the group consisting of amino acids 104, 105, 106, 107, 108 and 109 of SEQ ID NO:2, and y is selected from the group consisting of amino acids 304, 305, 306, 307, 308 and 309 of SEQ ID NO:2;
(b) a polypeptide comprising amino acids x through y SEQ ID NO:4, where x is selected from the group consisting of amino acids 49, 50, 51, 52, 53, and SEQ ID NO:4 and y is selected from the group consisting of amino acids 249, 250, 251, 252, 253 and 254 of SEQ ID NO:4;
(c) CD137L polypeptides that are at least about 80% identical in amino acid sequence to the polypeptides of (a) or (b); and
(d) fragments of the aforementioned CD137L polypeptides that are CD137 agonists.

### Claim 4 (depends on 2)

The method of claim 2, wherein the CD137 agonist is an agonistic antibody to CD137.

### Claim 5 (depends on 4)

The method of claim 4 wherein the antibody to CD137 is selected from the group consisting of:
(a) an antibody produced by hybridoma cell line 4-1BBm6, deposited with the American Type Culture Collection, in Manassas, Va. on Nov. 28, 2001 and given accession number PTA-3885;
(b) an antibody derived from the hybridoma cell line of (a); and
(c) derivative and mutants of the aforementioned antibodies, including scFv, Fab, F(ab′)2, diabodies, triabodies, IgA, IgG1, IgG2, IgG3, IgG4, IgM, IgE, IgD, and IgG4 having a mutation in a hinge region that alleviates a tendency to form intra-H chain disulfide bonds.

### Claim 6 (depends on 2)

The method of claim 2 wherein the condition mediated by IgE is selected from the group consisting of asthma, atopic dermatitis, allergy, and combinations thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the condition mediated by IgE is characterized by delayed eosinophil apoptosis.

### Claim 8 (depends on 6)

The method of claim 6 wherein the condition is selected from the group consisting of nasal polyps and hypereosinophilic syndrome.

### Claim 9 (depends on 2)

The method of claim 2 wherein the CD137 agonist is co-administered with an agent that antagonizes a cytokine selected from the group consisting of IL-4, IL-5, IL-9, IL-13, and combinations thereof.

### Claim 10 (depends on 9)

The method of claim 9 wherein the CD137 agonist is an antibody to CD137

### Claim 11 (depends on 2)

The method of claim 2 wherein the CD137 agonist is an antibody to CD137 and the conditioned mediated by IgE is asthma.

### Claim 12 (depends on 2)

The method of claim 2 wherein the CD137 agonist is co-administered with an anti-IgE antibody.

### Claim 13 (depends on 12)

The method of claim 12 wherein the CD137 agonist is an antibody to CD137.

### Claim 14 (depends on 3)

The method of claim 3 wherein the CD137 ligand is co-administered with an anti-IgE antibody.

### Claim 15 (depends on 14)

The method of claim 14 wherein the IgE mediated condition is asthma.
